EID Parry (India) Ltd
EID Parry (India) Ltd
ChemicalsKey Fundamentals
SmallcapFertilizersChemicalsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view EID Parry (India) Ltd insights
39 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 9.49% over last 3 years.
- Dividend payout has been low at 2.63% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -3.24%
Growth Rate
AI Analysis — Bull vs Bear
EID Parry (India) Ltd trades at a market cap of ₹14,166 crore with a PE of 10.4x while holding a ~56% stake in Coromandel International valued at approximately ₹31,000 crore — more than double its own market capitalisation. Consolidated FY25 revenue grew 7.5% YoY to ₹31,609 crore, but PAT declined to ₹878 crore from ₹900 crore in FY24, and the stock has corrected 31% over the past year.
- Deep holding-company discount: EID Parry's ~56% stake in Coromandel International alone is valued at ~₹31,000 crore versus its own market cap of ₹14,166 crore, implying the core sugar and other businesses are available at a significant discount
- Attractive valuation at a trailing PE of 10.4x, well below the broader market and many sugar-sector peers
- Consolidated revenue grew 7.5% YoY in FY25 to ₹31,609 crore despite sugar-sector headwinds, with standalone revenue up 12.8% to ₹3,168 crore
- TTM sales growth of 22% indicates strong recent top-line momentum beyond the 3-year CAGR of 3%
- Distillery capacity expanded to ~600 KLPD (from ~200 KLPD three-four years ago), positioning the company to benefit from India's E20 ethanol-blending mandate
- 10-year compounded profit CAGR of 35% demonstrates long-term earnings power across cycles
- Diversified operations across sugar (40,300 TCD crushing capacity), 140 MW co-generation, nutraceuticals, and refined sugar refining provide multiple revenue streams
- Stock has declined 31% over the past one year, significantly underperforming the broader market
- Low 3-year average ROE of 9.49%, indicating sub-par capital efficiency for shareholders
- Dividend payout of just 2.63% of profits over the last 3 years and current yield of only 0.5%, offering minimal income to shareholders despite repeated profitability
- Promoter holding decreased by 3.24% over the last 3 years, signalling potential lack of insider conviction
- 3-year compounded profit CAGR is negative at -11%, showing earnings have contracted on a medium-term basis
- Consolidated PAT declined to ₹878 crore in FY25 from ₹900 crore a year earlier, continuing a profit compression trend
- Holding-company discount may persist indefinitely without a catalyst such as demerger or stake monetisation, trapping value
- Sugar is a cyclical, government-regulated commodity, exposing standalone earnings to policy changes on MSP, export quotas, and cane pricing
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Independent Director retires from board Aug 4
Dr. Rea Godbole retired from EID Parry's board effective August 4, 2026, after completing two consecutive terms as Independent Director.
- BRSR sustainability report published Jul 20
EID Parry released its Business Responsibility and Sustainability Report for FY26, covering ESG initiatives, employee welfare, and environmental impact metrics.
- AGM scheduled for Aug 12 Jul 17
EID Parry's 51st AGM is set for August 12, 2026, with resolutions on financial adoption, director reappointment, PSRIPL asset disposal approval, and cost auditor remuneration ratification.
TL;DR: Recent news flow for EID Parry is entirely procedural and governance-related, with no material positive or negative catalysts. The company is fulfilling routine compliance obligations including board changes, sustainability reporting, and AGM scheduling. There are no visible headwinds or bullish triggers in recent coverage, suggesting a quiet period with no directional bias from news flow.
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,860 | 7,026 | 9,059 | 7,770 | 5,557 | 6,747 | 9,330 | 8,720 | 6,811 | 8,724 | 11,624 | 10,312 | 7,882 |
| Expenses | 6,245 | 6,363 | 8,006 | 7,358 | 5,098 | 6,279 | 8,372 | 8,027 | 6,298 | 7,918 | 10,427 | 9,477 | 7,271 |
| Operating Profit | 615 | 664 | 1,053 | 412 | 459 | 468 | 959 | 694 | 513 | 805 | 1,198 | 835 | 611 |
| OPM % | 9% | 9% | 12% | 5% | 8% | 7% | 10% | 8% | 8% | 9% | 10% | 8% | 8% |
| Other Income | 5 | -11 | 151 | 41 | 123 | 60 | 69 | 117 | 459 | 90 | 151 | 60 | -430 |
| Interest | 87 | 82 | 74 | 53 | 86 | 84 | 94 | 99 | 96 | 104 | 129 | 103 | 119 |
| Depreciation | 105 | 94 | 101 | 112 | 113 | 117 | 123 | 130 | 142 | 176 | 158 | 204 | 226 |
| PBT | 428 | 477 | 1,029 | 288 | 382 | 327 | 811 | 582 | 735 | 615 | 1,062 | 588 | -162 |
| Tax % | 33% | 32% | 24% | 25% | 23% | 31% | 27% | 29% | 27% | 25% | 28% | 26% | 77% |
| Net Profit | 287 | 325 | 782 | 217 | 294 | 226 | 592 | 416 | 539 | 464 | 766 | 437 | -287 |
| EPS in Rs | 10.08 | 6.13 | 25.48 | 6.66 | 12.41 | 5.14 | 17.21 | 10.97 | 16.12 | 13.85 | 23.86 | 13.05 | -18.74 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13,952 | 15,358 | 14,391 | 15,373 | 16,556 | 17,129 | 18,556 | 23,521 | 35,244 | 29,413 | 31,609 | 38,534 |
| Expenses | 12,938 | 14,517 | 12,965 | 14,068 | 15,105 | 15,242 | 16,467 | 21,146 | 32,088 | 26,825 | 28,975 | 35,085 |
| Operating Profit | 1,014 | 841 | 1,426 | 1,305 | 1,450 | 1,887 | 2,089 | 2,375 | 3,156 | 2,588 | 2,633 | 3,450 |
| OPM % | 7% | 5% | 10% | 8% | 9% | 11% | 11% | 10% | 9% | 9% | 8% | 9% |
| Other Income | 105 | 179 | 159 | 150 | 83 | 129 | 17 | 240 | 83 | 304 | 706 | -129 |
| Interest | 420 | 451 | 417 | 336 | 425 | 430 | 236 | 152 | 298 | 295 | 372 | 454 |
| Depreciation | 244 | 250 | 248 | 251 | 272 | 319 | 332 | 334 | 376 | 421 | 512 | 763 |
| PBT | 455 | 319 | 920 | 868 | 837 | 1,266 | 1,539 | 2,129 | 2,564 | 2,175 | 2,455 | 2,103 |
| Tax % | 39% | 45% | 23% | 40% | 48% | 30% | 35% | 26% | 29% | 26% | 28% | 34% |
| Net Profit | 276 | 175 | 708 | 517 | 438 | 889 | 1,000 | 1,574 | 1,828 | 1,618 | 1,773 | 1,380 |
| EPS in Rs | 6.64 | 1.96 | 29.61 | 14.45 | 8.67 | 26.43 | 25.26 | 51.12 | 53.37 | 50.68 | 49.41 | 32.02 |
| Div. Payout % | 89% | 0% | 14% | 21% | 35% | 0% | 0% | 22% | 18% | 8% | 0% | 0% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| Reserves | 2,209 | 2,370 | 2,733 | 2,952 | 3,110 | 3,502 | 4,565 | 5,308 | 6,067 | 7,040 | 7,918 | 8,748 |
| Borrowings | 4,823 | 5,144 | 3,923 | 4,470 | 5,125 | 4,347 | 1,229 | 1,259 | 1,618 | 1,740 | 2,704 | 3,528 |
| Other Liabilities | 5,849 | 6,600 | 6,691 | 7,088 | 7,649 | 7,069 | 7,444 | 9,358 | 11,076 | 12,688 | 13,731 | 16,917 |
| Total Liabilities | 12,899 | 14,131 | 13,364 | 14,528 | 15,901 | 14,936 | 13,257 | 15,943 | 18,778 | 21,487 | 24,371 | 29,212 |
| Fixed Assets | 3,476 | 3,343 | 3,297 | 3,197 | 3,077 | 3,858 | 3,583 | 3,763 | 3,889 | 4,896 | 6,148 | 8,240 |
| CWIP | 75 | 77 | 39 | 54 | 203 | 85 | 206 | 160 | 486 | 520 | 422 | 357 |
| Investments | 369 | 688 | 569 | 430 | 418 | 413 | 453 | 563 | 609 | 1,275 | 1,453 | 2,477 |
| Other Assets | 8,979 | 10,022 | 9,459 | 10,847 | 12,203 | 10,579 | 9,014 | 11,456 | 13,794 | 14,796 | 16,348 | 18,138 |
| Total Assets | 12,899 | 14,131 | 13,364 | 14,528 | 15,901 | 14,936 | 13,257 | 15,943 | 18,778 | 21,487 | 24,371 | 29,212 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 222 | 437 | 1,969 | 259 | -52 | 1,986 | 4,771 | 2,278 | 359 | 1,974 | 1,936 | 1,542 |
| Investing | -307 | -192 | -148 | 13 | -357 | -282 | -548 | -1,732 | 487 | -1,740 | -2,783 | -173 |
| Financing | -142 | -221 | -1,842 | 42 | 34 | -1,769 | -3,598 | -499 | -184 | -497 | 74 | -551 |
| Net Cash Flow | -227 | 23 | -21 | 314 | -375 | -65 | 625 | 47 | 661 | -263 | -772 | 818 |
| Free Cash Flow | 35 | 233 | 1,839 | 82 | -396 | 1,628 | 4,455 | 1,845 | -370 | 1,051 | 1,323 | 5 |
| CFO/OP | 36 | 73 | 160 | 48 | 24 | 126 | 252 | 117 | 33 | 101 | 102 | 67 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45 | 49 | 47 | 43 | 46 | 45 | 17 | 9 | 8 | 23 | 20 | 22 |
| Inventory Days | 138 | 124 | 127 | 134 | 175 | 131 | 112 | 111 | 81 | 112 | 101 | 107 |
| Days Payable | 141 | 145 | 170 | 174 | 172 | 141 | 124 | 114 | 84 | 121 | 113 | 116 |
| Cash Conversion Cycle | 42 | 27 | 4 | 3 | 49 | 35 | 6 | 6 | 5 | 14 | 8 | 13 |
| Working Capital Days | -1 | 2 | 15 | 4 | 17 | 36 | 45 | 29 | 27 | 27 | 14 | 21 |
| ROCE % | 11% | 9% | 16% | 16% | 14% | 18% | 21% | 26% | 27% | 20% | 17% | 17% |
Documents
Frequently Asked Questions about EID Parry (India) Ltd
What does EID Parry (India) Ltd do?
Where is EID Parry (India) Ltd (EIDPARRY) listed?
Which sector does EID Parry (India) Ltd belong to?
What is the market capitalisation of EID Parry (India) Ltd?
What is the PE ratio of EID Parry (India) Ltd?
What is the 52-week high and low of EID Parry (India) Ltd?
Does EID Parry (India) Ltd pay dividends?
What is the Return on Equity (ROE) of EID Parry (India) Ltd?
How can I research EID Parry (India) Ltd on Tapetide?
Company Information
EID Parry is engaged in Sugar, Nutraceuticals and ethanol production. It also has a significant presence in the Farm Inputs business including Bio pesticides through its subsidiary, Coromandel International Limited. [1]